Compliance Management

FDA Warns ABX Weight Loss Has Hidden Danger

Nov 16, 2016

The U.S. FDA is advising consumers not to purchase or use ABX Weight Loss, a product promoted and sold for weight loss on the website,, and possibly in some retail stores. 

FDA laboratory analysis confirmed that ABX Weight Loss contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some people and may present a significant risk for people with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.

Health care professionals and patients are encouraged to report adverse events or side effects related to the use of this product to FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Complete and submit the report online MedWatch Online Voluntary Reporting Form, or: download and complete the form, then submit it via fax at 1-800-FDA-0178.